

Supplementary Information

Cryptic U2-dependent pre-mRNA splice site usage induced by splice switching antisense oligonucleotides

Kristin A. Ham^{1,2¶}, Niall P. Keegan^{1,2¶}, Craig S. McIntosh^{1,2}, May T. Aung-Htut^{1,2}, Khine Zaw¹⁻³, Kane Greer^{1,2}, Sue Fletcher^{1,2} and Steve D. Wilton^{1,2*}

¹ Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, Western Australia, 6150, Australia

² Perron Institute for Neurological and Translational Science, Centre for Neuromuscular and Neurological Disorders, The University of Western Australia, Perth, Western Australia, 6009, Australia


³ Department of Biochemistry, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand

* corresponding author s.wilton@murdoch.edu.au


¶ these authors contributed equally to this work

Supplementary Figure S1

a



b



Supplementary Figure 1. Analysis of antisense oligonucleotide-mediated splice switching in *SRSF2* gene transcripts. (a) Full gel image of reverse transcription-PCR analysis after transfection with antisense oligonucleotides (AOs), at various nM concentrations indicated above the gel image. (b) Alternative transcript exon composition before and after AO treatment. Blue boxes represent exons, lines between the boxes

represent introns, dashed lines above and below represent various splicing events, red polygons represent termination codons, pink boxes represent the exon portion removed after the activation of a cryptic splice site, pink polygons represent termination codons removed after cryptic splice site activation. Multiple transcript isoforms noted as T### according to Ensembl. Question mark (?) indicates an amplicon that could not be successfully isolated and sequenced. NC, negative control sequence synthesized as 2'-OMe PS; UT, untreated; 100 bp, 100 base pair DNA ladder; nM, nanomolar; NMD, nonsense mediated decay.